[go: up one dir, main page]

WO2012129399A3 - Compositions for and methods of evaluating tumors having a skeletal muscle origin - Google Patents

Compositions for and methods of evaluating tumors having a skeletal muscle origin Download PDF

Info

Publication number
WO2012129399A3
WO2012129399A3 PCT/US2012/030112 US2012030112W WO2012129399A3 WO 2012129399 A3 WO2012129399 A3 WO 2012129399A3 US 2012030112 W US2012030112 W US 2012030112W WO 2012129399 A3 WO2012129399 A3 WO 2012129399A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
evaluating
skeletal muscle
tumors
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/030112
Other languages
French (fr)
Other versions
WO2012129399A2 (en
Inventor
Eyas M. HATTAB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of WO2012129399A2 publication Critical patent/WO2012129399A2/en
Anticipated expiration legal-status Critical
Publication of WO2012129399A3 publication Critical patent/WO2012129399A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Myoblastic differentiation biomarkers are provided for evaluating tumors having a skeletal muscle origin. In addition, kits are provided for evaluating expression levels or presence of the biomarkers associated with such tumors. Furthermore, methods are provided for evaluating such tumors via measuring expression levels or presence of the biomarkers in the cytoplasm of cells.
PCT/US2012/030112 2011-03-22 2012-03-22 Compositions for and methods of evaluating tumors having a skeletal muscle origin Ceased WO2012129399A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161466289P 2011-03-22 2011-03-22
US61/466,289 2011-03-22

Publications (2)

Publication Number Publication Date
WO2012129399A2 WO2012129399A2 (en) 2012-09-27
WO2012129399A3 true WO2012129399A3 (en) 2014-05-01

Family

ID=46880040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/030112 Ceased WO2012129399A2 (en) 2011-03-22 2012-03-22 Compositions for and methods of evaluating tumors having a skeletal muscle origin

Country Status (1)

Country Link
WO (1) WO2012129399A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211503A1 (en) * 2001-10-01 2003-11-13 Carpentieri David F. Materials and methods for the diagnosis of pediatric tumors
US6972181B2 (en) * 2001-01-12 2005-12-06 Mount Sinai School Of Medicine Of New York University Differential diagnosis of cancer and other conditions based on expression of p63
US20100215647A1 (en) * 2007-06-26 2010-08-26 Vanderbilt University Immunological Compositions as Cancer Biomarkers and/or Therapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972181B2 (en) * 2001-01-12 2005-12-06 Mount Sinai School Of Medicine Of New York University Differential diagnosis of cancer and other conditions based on expression of p63
US20030211503A1 (en) * 2001-10-01 2003-11-13 Carpentieri David F. Materials and methods for the diagnosis of pediatric tumors
US20100215647A1 (en) * 2007-06-26 2010-08-26 Vanderbilt University Immunological Compositions as Cancer Biomarkers and/or Therapeutics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARPENTIERI ET AL.: "The Expression of WT1 in the Differentiation of Rhabdomyosarcoma from Other Pediatric Small Round Blue Cell Tumors.", MOD PATHOL., vol. 15, 2002, pages 1080 - 1086 *
DIAS ET AL.: "Myogenic Regulatory Protein (MyoD1) Expression in Childhood Solid Tumors: Diagnostic Utility in Rhabdomyosarcoma.", AMER J OF PATHOLOGY, vol. 137, 1990, pages 1283 - 1291 *
MARTIN ET AL.: "Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study.", MOD PATHOL. 2011, vol. 24, no. 10, 27 May 2011 (2011-05-27), pages 1320 - 1326 *

Also Published As

Publication number Publication date
WO2012129399A2 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
WO2013163568A3 (en) Methods for evaluating lung cancer status
EP4450644A3 (en) Increasing dynamic range for identifying multiple epitopes in cells
WO2009129505A3 (en) Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid
MX2019015159A (en) Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis.
WO2011156654A3 (en) Pathways characterization of cells
WO2012056457A3 (en) Compositions and methods for activating expression by a specific endogenous mirna
HK1214652A1 (en) Methods and compositions for detecting pancreatic cancer
BRPI0911038A2 (en) methods for expressing a heterologous sequence in a host cell and for producing an isoprenoid in a host cell, host cell, expression vector, expression vector set, kit, and cell culture.
WO2010088668A3 (en) Methods of detecting sepsis
WO2011106709A3 (en) Epithelial biomarkers for cancer prognosis
WO2013049152A3 (en) Methods for evaluating lung cancer status
WO2013025322A3 (en) Marker-based prognostic risk score in liver cancer
WO2012033537A8 (en) Benchmarks for normal cell identification
HK1197273A1 (en) Methods and materials related to ovarian cancer
WO2012103355A3 (en) Methods of detecting lung cancer
EP2547782B8 (en) Methods, kits and compositions for detection of mrsa
WO2013188469A3 (en) Pathways characterization of cells
WO2012058313A3 (en) Novel biomarkers for cardiovascular injury
WO2011119986A3 (en) Methods for culturing and analyzing cells
GB2496557A (en) Products and methods for identifying rock samples
WO2013040251A3 (en) Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2012164525A3 (en) Aging biomarkers
WO2013082249A3 (en) Compositions and methods for prostate cancer analysis
HK1205558A1 (en) Methods and biomarkers for detection and prognosis of cervical cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12760031

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12760031

Country of ref document: EP

Kind code of ref document: A2